Australia markets open in 4 hours 29 minutes

Apogee Therapeutics, Inc. (APGE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
21.48-0.26 (-1.20%)
At close: 04:00PM EST
21.48 0.00 (0.00%)
After hours: 04:02PM EST
Full screen
Trade prices are not sourced from all markets
Previous close21.74
Bid8.61 x 2900
Ask34.41 x 800
Day's range20.62 - 22.94
52-week range14.19 - 25.54
Avg. volume372,695
Market cap1.088B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.00
  • Simply Wall St.

    We Think Apogee Therapeutics (NASDAQ:APGE) Can Easily Afford To Drive Business Growth

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

    Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected mid-2024; on track to begin Phase 2 in moderate-to-severe atopic dermatitis in 2024 Announcing our finalized nomination of development candidate for APG808, a potentially best-in-class, femtomolar affinity, subcutaneous extended half-life antibody targeting IL-4Rα, a target with clinical validation

  • GlobeNewswire

    Apogee Therapeutics to Participate in Upcoming November Investor Conferences

    SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease and other inflammatory and immunology indications, today announced that management will present at the following upcoming investor conferences: Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference Date: